The phospholipid phosphatidylserine (PS) is an early marker exploited for detecting apoptosis (PS externalization in the cell membrane bilayer) and one factor that is associated with increased amyloid plaque deposition in transmissible spongiform encephalopathies (TSEs). PS can therefore be considered as a promising target for diagnosis or treatment of diseases. Aptamers (short nucleic acid sequences) are a particularly attractive class of materials among those currently considered for targeting PS. Here we applied an entropy based seed-and-grow strategy to design a DNA aptamer template to bind specifically to PS. The binding properties of designed aptamers were investigated computationally and experimentally. The studies identify the sequence, 5′-AAAGAC-3′, as the preferred template for further modifications and studies toward its practical implementations.
Get full access to this article
View all access options for this article.
References
1.
ASHRAFUZZAMANM., TSENGC.-Y., DUSZYKM., and TUSZYNSKIJ. (2012). Chemotherapy drugs form ion pores in membranes due to physical interactions with lipids. Chem. Biol. Drug. Des., 80, 992–1002.
2.
ASHRAFUZZAMANM., and TUSZYNSKIJ. (2012). Regulation of channel function due to coupling with a lipid bilayer. J. Comput. Theor. Nanosci., 9, 564–570.
3.
BLANKENBERGF.G. (2009). Imaging the molecular signatures of apoptosis and injury with radiolabeled annexin V. Proc. Am.Thorac. Soc., 6, 469–476.
4.
BOERSMAH.H., KIETSELAERB.L., STOLKL.M., BENNAGHMOUCHA., HOFSTRAL., NARULAJ., HEIDENDALG.A., and REUTELINGSPERGERC.P. (2005). Past, present, and future of annexin A5: from protein discovery to clinical applications. J. Nucl. Med., 46, 2035–2050.
5.
CAMPANAV., ZENTILINL., MIRABILEI., KRANJCA., CASANOVAP., GIACCAM., PRUSINERS.B., LEGNAMEG., and ZURZOLOC. (2009). Development of antibody fragments for immunotherapy of prion diseases. Biochem. J., 418, 507–515.
6.
CASED.A., DARDENT.A., CHEATHAMT.E.III, SIMMERLINGC.L., WANGJ., DUKER.E., LUOR., CROWLEYM., WALKERR.C., ZHANGW., et al. (2008). AMBER 10. (University of California, San Francisco).
7.
CASED.A., DARDENT.A., CHEATHAMT.E.III, SIMMERLINGC.L., WANGJ., DUKER.E., LUOR., CROWLEYM., WALKERR.C., ZHANGW., et al. (2010). AMBER 11. (University of California, San Francisco)
8.
CATICHAA. (2004). Relative entropy and inductive inference. In: Bayesian Inference and Maximum Entropy Methods in Science and Engineering. EricksonG., ZhaiY. ed. AIP Conf. Proc., 707 (American Institute of Physics, Melville, New York), pp. 75–96.
9.
CATICHAA., and GIFFINA. (2007). Updating probabilities. In: Bayesian Inference and Maximum Entropy Methods in Science and Engineering. KnuthK. H., CatichaA., CenterJ. L., GiffinA., RodriguezC. C. ed. AIP Conf. Proc., 954 (American Institute of Physics, Melville, New York), pp. 74–84.
10.
CHENC.-C., TSENGC.-Y., and DONGJ.-J. (2007). New entropy-based method for variables selection and its application to the debris flow hazard assessment. Eng. Geol., 94, 19–24.
11.
CHIESAR., DRISALDIB., QUAGLIOE., MIGHELIA., PICCARDOP., GHETTIB., and HARRISD.A. (2000). Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation. Proc. Natl. Acad. Sci., 97, 5574–5579.
12.
ELMORES. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol., 35, 495–516.
13.
GOUTELLES., MAURINM., ROUGIERF., BARBAUTX., BOURGUIGNONL., DUCHERM., and MAIREP. (2008). The Hill equation: a review of its capabilities in pharmacological modeling. Fundam. Clin. Pharmacol., 22, 633–648.
14.
HAMULAC.L.A., GUTHRIEJ.W., ZHANGH., LIX.F., and CHRIS LEX. (2006). Selection and analytical applications of aptamers. Trends Anal. Chem., 25, 681–691.
15.
HEPPNERF.L., and AGUZZIA. (2004). Recent developments in prion immunotherapy. Curr. Opin. Immunol., 16, 594–598.
16.
HOPEM.J., BALLYM.B., MAYERL.D., JANOFFA.S., and CULLISP.R. (1986). Generation of multilamellar and unilamellar phospholipid vesicles. Chem. Phys. Lipids, 40, 89–107.
17.
HUMPHREYW., DALKEA., and SCHULTENK. (1996). VMD: Visual molecular dynamics. J. Mol. Graph, 14, 33–38.
18.
JAMESW. (2000). Aptamers. In: Encyclopedia of Analytical Chemistry. MeyersR. A. ed. (John Wiley & Sons, Ltd., Chichester), pp. 4878–4871.
19.
JAMESW. (2007). Aptamers in the virologists' toolkit. J. Gen.Virol., 88, 351–364.
20.
JAYNESE.T. (1957a) Information theory and statistical mechanics. Phys. Rev., 106, 620–630.
21.
JAYNESE.T. (1957b) Information theory and statistical mechanics II. Phys. Rev., 108, 171–190.
22.
KAPTYJ., BANMANS., GOPINGI.S., and MERCERJ.R. (2012). Evaluation of Phosphatidylserine-Binding Peptides Targeting Apoptotic Cells. J. Biomol. Screen., 17, 1293–1301.
23.
KEEFEA.D., PAIS., and ELINGTONA. (2010). Aptamers as therapeutics. Nature Rev. Drug Discov., 9, 537–550.
24.
KERRJ.F., WYLLIEA.H., and CURRIEA.R. (1972). Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer, 4, 239–257.
25.
LAOY.H., PECKK., and CHENL.C. (2009). Enhancement of aptamer microarray sensitivity through spacer optimization and avidity effect. Anal. Chem., 81, 1747–1754.
26.
MARTINS.J.,; REUTELINGSPERGERC.P., MCGAHONA.J., RADERJ.A., VAN SCHIER.C., LAFACED.M., and GREEND.R. (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med., 182, 1545–1556.
27.
NIMJEES.M., RUSCONIC.P., and SULLENGERB.A. (2005). Aptamers: an emerging class of therapeutics. Annu. Rev. Med., 56, 555–583.
QUADRIOI., PERRET-LIAUDETA., and KOVACSG.G. (2011). Molecular diagnosis of human prion disease. Expert. Opin. Med. Diag., 5, 291–230.
30.
RASTOGIR.P., RICHA, and SINHAR.P. (2009). Apoptosis: molecular mechanisms and pathogenicity EXCLI. J., 8, 155–181.
31.
RHIEA., KIRBYL., SAYERN., WELLESLEYR., DISTERERP., SYLVESTERI., GILLA., HOPEJ., JAMESW., and TAHIRI-ALAOUIA. (2003). Characterization of 2-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion. J. Bio. Chem., 278, 39697–39705.
32.
ROBINSONP.J., and PINHEIROT.J. (2010). Phospholipid composition of membranes directs prions down alternative aggregation pathways. Biophys. J., 98, 1520–1528.
33.
SHOREJ.E., and JOHNSONR.W. (1980). Axiomatic derivation of the principle of maximum entropy and the principle of minimum cross entropy. IEEE Trans. Inf. Theory, 26, 26–37.
34.
SHOREJ.E., and JOHNSONR.W. (1981). Properties of cross-entropy minimization. IEEE Trans. Inf. Theory, 27, 472–482.
35.
SMRZD., LEBDUSKAP., DRÁBEROVÁL., KORBJ., and DRÁBERP. (2008). Engagement of phospholipid scramblase 1 in activated cells: implication for phosphatidylserine externalization and exocytosis. J. Biol. Chem., 283, 10904–10918.
36.
THELLUNGS., CORSAROA., VILLAV., SIMIA., VELLAS., PAGANOA., and FLORIOT. (2011). Human PrP90-231-induced cell death is associated with intracellular accumulation of insoluble and protease-resistant macroaggregates and lysosomal dysfunction. Cell Death Dis. 2,e138.
37.
TSENGC.-Y. (2006). Entropic criterion for model selection. Physica A, 370, 530–538.
38.
TSENGC.-Y., and CatichaA. (2008). Using relative entropy to find optimal approximations: an application to simple fluids. Physica A, 387, 6759–6770.
39.
TSENGC.-Y., ASHRAFUZZAMANMD, MANEJ., KAPTYJ., MERCERJ., and TUSZYNSKIJ. (2011). Entropic fragment based approach to aptamer design. Chem. Biol. Drug Design, 78, 1–13.
40.
TUERKC., and GOLDL. (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505–510.
41.
VAN MEERG., VOELKERD.R., and FEIGENSONG.W. (2008). Membrane lipids: where they are and how they behave. Nature Rev. Mol. Cell Biol., 9, 112–124.
42.
WANGJ., WOLFR.M., CALDWELLJ.W., KOLLMANP.A., and CASED.A. (2004). Development and testing of a general AMBER force field. J. of Comp. Chem., 25, 1157–1174.
43.
WANGJ., WANGW., KOLLMANP.A., and CASED.A. (2006). Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph Model, 25, 247–260.
44.
WEINBERGR.A. (2007). The biology of cancer. (Garlan Science, New York)
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
